[{"id":"3328155d-7553-48a6-b065-e0041a8e5d51","acronym":"","url":"https://clinicaltrials.gov/study/NCT04844073","created_at":"2021-04-14T11:52:51.365Z","updated_at":"2025-02-25T17:37:05.429Z","phase":"Phase 1/2","brief_title":"A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer","source_id_and_acronym":"NCT04844073","lead_sponsor":"Takeda","biomarkers":" PD-L1 • KRAS • MSI","pipe":" | ","alterations":" MSI-H/dMMR • PD-L1 negative","tags":["PD-L1 • KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAK-186"],"overall_status":"Recruiting","enrollment":" Enrollment 258","initiation":"Initiation: 03/08/2021","start_date":" 03/08/2021","primary_txt":" Primary completion: 09/27/2025","primary_completion_date":" 09/27/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-29"},{"id":"01bab055-3bba-471a-9ff9-022c1458fb21","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891718","created_at":"2021-05-18T12:02:12.873Z","updated_at":"2025-02-25T14:59:52.160Z","phase":"Phase 1","brief_title":"CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia","source_id_and_acronym":"NCT04891718","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • TAK-186"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 06/05/2022","primary_completion_date":" 06/05/2022","study_txt":" Completion: 06/05/2022","study_completion_date":" 06/05/2022","last_update_posted":"2022-07-08"}]